Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758573 | 0.88 | MAPK14 (0.52) | USP2CYP1A2CYP3A4HPGDCASP1 | |
| SCHEMBL1758171 | 0.88 | KDM1A (0.50) | USP2CYP1A2CYP3A4HPGDABCG2 | |
| SCHEMBL1758211 | 0.87 | MAPK14 (0.56) | USP2CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL1758075 | 0.84 | LMNA (0.47) | USP2CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL1758186 | 0.84 | ABCG2 (0.51) | CYP1A2CYP3A4HPGDABCG2ACP1 | |
| SCHEMBL12646744 | 0.84 | KDM1A (0.44) | USP2CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL1758206 | 0.82 | KMT2A (0.60) | USP2CYP1A2CYP3A4HPGDCASP1 | |
| SCHEMBL1758319 | 0.81 | RAF1 (0.41) | USP2CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL1758114 | 0.81 | KDM1A (0.59) | USP2CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL1757893 | 0.81 | ACP1 (0.46) | USP2CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633718-B1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2012-06-06 | — | — | EP | claimed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | claimed |
| EP-1633718-A4 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2008-11-19 | — | — | EP | claimed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | claimed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | claimed |
| EP-1633718-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050032835-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| WO-2004112710-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | TGFBR1, TGFB1, TGFBR2 | USP2 3682/4885CYP1A2 2019/4885CYP3A4 1463/4885 |
| US-20050032835-A1 | Compositions and methods for inhibiting TGF-beta | TGFBR1, TGFB1, TGFBR2 | USP2 3682/4885CYP1A2 2019/4885CYP3A4 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.